Societal CDMO, Inc.
DelistedCIK 1588972fmd_0G1MCCMJR9PC5S6YXMH18SKPGBManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Dec 31, 2023, 44 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 52 | 69 | 72 | 77 | 99 | 66 | 75 | 90 | 95 |
| Cost of revenue | – | 28 | 37 | 38 | 43 | 51 | 54 | 56 | 67 | 76 |
| Gross profit | – | 24 | 32 | 34 | 34 | 48 | 12 | 20 | 23 | 18 |
| Research and development | 8 | 12 | 33 | 4 | 4 | – | – | – | – | – |
| Selling, general and administrative | – | – | – | 14 | 14 | 20 | 18 | 18 | 22 | 21 |
| Total operating expenses | 12 | – | – | – | – | – | – | – | – | – |
| Operating income | (12) | (7) | (26) | (40) | 12 | 24 | (8) | 0 | 0 | (4) |
| Interest expense | 4 | 6 | 6 | 12 | 8 | 19 | 19 | 15 | 14 | 10 |
| Interest and investment income | 0 | 0 | 0 | 0 | 1 | 1 | – | – | – | – |
| Other non-operating income (expense) | (4) | – | – | – | – | – | – | 0 | 0 | 0 |
| Income before taxes | (16) | (13) | (31) | 12 | 12 | 24 | (28) | (11) | (19) | (13) |
| Income tax expense | – | (16) | (1) | 7 | 17 | 0 | 0 | 0 | 1 | 0 |
| Net income from continuing operations | – | 3 | (30) | (7) | (13) | 5 | (28) | (11) | (20) | (13) |
| Net income | (16) | 3 | (30) | (50) | (80) | (19) | (28) | (11) | (20) | (13) |
| Net income to common shareholders | (17) | 3 | (30) | (50) | (80) | (19) | – | – | – | – |